Welcome to BREATHER Plus

BREATHER Plus investigated whether young people living with HIV were able to safely take weekends off dolutegravir-based HIV treatment.

BREATHER Plus was a randomised open-label two-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa.

The BREATHER Plus trial results were presented at the IAS Conference on HIV Science in Kigali, Rwanda (July 2025). See the link to the news article here: Young people living with HIV should take their HIV medicines daily | MRC Clinical Trials Unit at UCL